Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

Journal of Neurology
A AchironR Achiron

Abstract

Acute exacerbations may complicate the course of pregnancy and the postpartum period in patients with relapsing-remitting multiple sclerosis (RRMS). To evaluate relapse rate and the effect of immunomodulatory treatment with intravenous immunoglobulin (IVIg) during pregnancy and the postpartum period we retrospectively analysed the data of 108 pregnant RRMS patients. Group I patients were not treated, Group II patients were treated with IVIg 0.4 g/kg body weight/day for 5 consecutive days within the first week after delivery with additional booster doses of 0.4 g/kg body weight/day at 6 and 12 weeks postpartum (defined as 12 weeks after labor), and Group III patients were treated continuously with IVIg during gestation and the postpartum period (0.4 g/kg body weight/day for 5 consecutive days within the 6-8 weeks of gestation with additional booster doses of 0.4 g/kg body weight/day once every 6 weeks until 12 weeks postpartum). All patients underwent antenatal care and fetal ultrasonographic surveillance examinations. Relapse rate per woman per year during the pregnancy and the postpartum period as well as neonatal outcome data and IVIg related adverse events were analysed. Relapse rate per woman per year for patients treated w...Continue Reading

Citations

Feb 10, 2006·Der Nervenarzt·L A HoffmannR Hohlfeld
Dec 1, 2006·Der Nervenarzt·Peter Rieckmann, Peter Rieckmann
Aug 6, 2008·Der Nervenarzt·S Cursiefen, M Mäurer
Aug 8, 2009·Der Nervenarzt·S SchwarzB Storch-Hagenlocher
Feb 16, 2006·Journal of Neurology·Martin StangelUwe K Zettl
Sep 26, 2006·Journal of Neurology·Ales Dudesek, Uwe K Zettl
Sep 26, 2006·Journal of Neurology·Isabel Ringel, Uwe K Zettl
Nov 14, 2008·Journal of Neurology·UNKNOWN Multiple Sclerosis Therapy Consensus Group (MSTCG)R Hohlfeld
Aug 29, 2012·Journal of Neurology·Maria K Houtchens, Channa M Kolb
Mar 14, 2007·Journal of Clinical Immunology·Vir-Singh NegiSrini V Kaveri
Jun 25, 2013·Trends in Pharmacological Sciences·Mathias ButtmannHans-Peter Hartung
Sep 1, 2008·Therapeutic Advances in Neurological Disorders·Martin Stangel
Aug 29, 2012·Clinical Ophthalmology·John H Pula, Christopher J Macdonald
Apr 2, 2014·Revue neurologique·E BodiguelJ De Seze
Feb 26, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Annette Langer-Gould, Brandon E Beaber
Dec 2, 2010·Women's Health·Céline JobinPierre Duquette
Jul 5, 2012·Women's Health·Sura Alwan, A Dessa Sadovnick
Oct 25, 2006·Autoimmunity·Uriel KatzAnat Achiron
Jun 19, 2012·The Medical Clinics of North America·Donna Graves, Steven Vernino
Jul 31, 2012·Neurologic Clinics·P K Coyle
May 23, 2015·Acta Neurologica Scandinavica·S Živković
Sep 9, 2008·Drug Discovery Today·Georg PilzJörg Kraus
Jul 1, 2014·TheScientificWorldJournal·Ioan Buraga, Roxana-Elena Popovici
Jan 22, 2008·Acta Neurologica Scandinavica·K HellwigR Gold
Jan 22, 2005·Neurologic Clinics·Patricia K Coyle
Feb 18, 2014·Journal of the American Academy of Dermatology·Daniel C ButlerJenny E Murase
Sep 5, 2014·Health Care for Women International·Yara Dadalti FragosoDenis Evandro Zani
Apr 9, 2011·Journal of Neuroimmunology·Judith M Greer, Pamela A McCombe
Apr 26, 2006·Expert Opinion on Pharmacotherapy·Valentina Tomassini, Carlo Pozzilli
May 25, 2015·Trends in Pharmacological Sciences·Jagadeesh BayrySrini V Kaveri
Jan 10, 2012·Journal of Autoimmunity·Leesa M PennellEleanor N Fish
Apr 22, 2015·Nature Reviews. Neurology·Sandra Vukusic, Romain Marignier
May 15, 2016·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Evelyn Brandt-WoutersRaymond M M Hupperts
Jul 31, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Gianluca SerafiniPaolo Girardi
Mar 3, 2015·Neurología : publicación oficial de la Sociedad Española de Neurología·J P CuelloC de Andrés
Jan 7, 2015·Nature Reviews. Neurology·Jan D LünemannMarinos C Dalakas
Mar 20, 2015·Multiple Sclerosis and Related Disorders·Sura AlwanA Dessa Sadovnick
Feb 2, 2010·La Presse médicale·Thibault MoreauAgnès Fromont
Jan 10, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Emilio PortaccioUNKNOWN MS Study Group of the Italian Neurological Society
Aug 27, 2010·Neurología : publicación oficial de la Sociedad Española de Neurología·A García MerinoT Arbizu
Jan 22, 2014·Multiple Sclerosis : Clinical and Laboratory Research·David H MillerMaria Trojano
Oct 12, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Sandra VukusicChristian Confavreux
Jun 27, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Pamela A McCombe, Judith M Greer
Oct 11, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Stella E HughesUNKNOWN MSBase study group
Apr 29, 2016·Journal of Perinatal Medicine·Serenat Eris YalcinMekin Sezik
Apr 12, 2005·La Revue de médecine interne·A Boughammoura-BouatayM Frih-Ayed
Jan 18, 2006·Clinical Neurology and Neurosurgery·Sandra Vukusic, Christian Confavreux
Aug 23, 2016·Neurología : publicación oficial de la Sociedad Española de Neurología·M Mendibe BilbaoA Rodriguez-Antigüedad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.